TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com) is pleased to announce that it has received a Health Canada Medical Device License for the Novasight HybridTM System. This patented technology is the only clinical system that enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT), and was […]
Coronary/Structural Heart
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
ANN ARBOR, Mich., March 13, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today in The New England Journal of Medicine (NEJM). Bempedoic acid is being […]
Bay Labs’ New Studies at ACC.19 Demo Accuracy, Efficiency and Reproducibility of its AI Software
SAN FRANCISCO – March 13, 2019 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, today announced the presentation of two studies assessing performance of the company’s deep learning software. The first evaluated the company’s software when used by medical professionals […]
Bay Labs Announces New Data that Evaluates Accuracy, Efficiency and Reproducibility of EchoGPS™ and AutoEF AI Software
Bay Labs Announces New Data that Evaluates Accuracy, Efficiency and Reproducibility of EchoGPS™ and AutoEF AI Software Results Presented at the American College of Cardiology ACC.19 68th Annual Scientific Session SAN FRANCISCO – March 13, 2019 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) […]
Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
CAESAREA, Israel, March 12, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that Gilad Glick, Chief Executive Officer of Itamar Medical, will […]
AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019
WILMINGTON, Del.–(BUSINESS WIRE)–Data evaluating the cardiovascular (CV) effects of FARXIGA® (dapagliflozin),including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on March 16-18. The data are the […]
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
BASKING RIDGE, N.J., March 11, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select […]
Ablative Solutions Announces Results from Treatment of Patients with Hypertension in the European Peregrine Post-Market Study
KALAMAZOO, Mich. & WASHINGTON–(BUSINESS WIRE)–Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced new data from the Peregrine Post-Market Clinical Trial, which were presented this week during a late-breaking session at the 2019 Cardiovascular Research Technologies (CRT) meeting in Washington, D.C. The Peregrine Post-Market […]
BTG Crossing Devices are Highlighted at the CTO Summit in NY
BOTHELL, WA, March 7, 2019 /PRNewswire/ — BTG plc (LSE: BTG), the global healthcare company, exhibited the BTG Crossing Devices portfolio at the Chronic Total Occlusion (CTO) Summit in New York City from February 28 to March 1. Dr. Alexandre Avran of the Arnault Tzanck Institute in Nice, France, headlined the BTG exhibition at the summit this year, discussing his experience […]
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1 as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts […]
Recent
Popular
- No commented posts yet